Growth Hormone
Sermorelin Dosage Protocol
A synthetic GHRH analog (first 29 AA) with preserved physiologic GH feedback, formerly FDA-approved as Geref. Complete titration schedule, special storage instructions, and peer-reviewed references.
Last reviewed March 2025 · 2 cited sources
Reconstitution
Add 3.0 mL BAC water → 1.67 mg/mL
Daily dose range
200–500 mcg (titrated)
Unit math (U-100 syringe)
1 unit = 0.01 mL ≈ 16.7 mcg
Storage (lyophilized)
Refrigerate at 2–8 °C (REFRIGERATE -do NOT freeze) · Reconstituted: 36–46 °F · Use within 10–14 days
Dosing & Reconstitution Guide
The protocol below uses a 3.0 mL reconstitution volume to keep injection units comfortably above 10 on a standard U-100 insulin syringe, reducing measurement error. Doses are titrated as shown below.
| Phase |
Daily dose |
U-100 units |
Injection volume |
| Weeks 1–2 | 200 mcg | 12 units | 0.12 mL |
| Weeks 3–4 | 300 mcg | 18 units | 0.18 mL |
| Weeks 5–6 | 400 mcg | 24 units | 0.24 mL |
| Weeks 7–8+ | 500 mcg | 30 units | 0.30 mL |
Route: Subcutaneous · Frequency: Once daily SC AT BEDTIME · Cycle: 3–6 months
Reconstitution steps
01
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
02
Inject the water slowly down the interior wall of the peptide vial -never directly onto the powder -to prevent foaming and denaturation.
03
Swirl or roll gently until fully dissolved. Do not shake. The lyophilized powder should dissolve completely within 30–60 seconds.
04
Label the vial with the reconstitution date and concentration (1.67 mg/mL). Refrigerate at 36–46 °F, protected from light. Use within 10–14 days.
Research use only. This protocol is derived from published preclinical and early-phase clinical literature. Sermorelin is not FDA-approved for human use. This information is not medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before beginning any peptide protocol.
Supplies Needed
Estimates below assume the titration schedule listed above.
Sermorelin vials (5 mg each)
Per cycleAs needed per titration
U-100 insulin syringes
8 weeks56 syringes
12 weeks84 syringes
16 weeks112 syringes
Bacteriostatic water (10 mL bottles)
Alcohol swabs (100-count boxes)
8 weeks2 boxes (~112 swabs)
12 weeks2 boxes (~168 swabs)
16 weeks3 boxes (~224 swabs)
Storage Instructions
Lyophilized (dry powder)
2–8 °C (REFRIGERATE -do NOT freeze)
Store refrigerated in dry, dark conditions. Do not freeze.
Reconstituted (in solution)
36–46 °F
Refrigerate after reconstitution. Use within 10–14 days. Do not refreeze reconstituted solution -freeze-thaw cycles degrade peptide integrity.
Allow refrigerated vials to reach room temperature before opening to minimize condensation uptake. Always inspect for cloudiness or particulates before use -discard if present.
We recommend Pacific Edge Labs for research-grade Sermorelin. Third-party lab tests are published on each product page.
Why Pacific Edge Labs
- High-purity compounds with third-party lab results available on the website
- Consistent quality control with ISO-aligned handling and documentation
- Fast, discreet shipping with proper handling and packaging
View Sermorelin on Pacific Edge Labs →
How Sermorelin Works
Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH 1-29). Unlike exogenous GH, Sermorelin works through the hypothalamic-pituitary axis, stimulating pituitary somatotrophs to release GH while preserving the physiologic negative feedback loop (somatostatin and IGF-1 inhibition prevent supraphysiologic GH levels).[1]
Sermorelin was previously FDA-approved as Geref for diagnostic and therapeutic use. Bedtime administration is critical -timing amplifies the natural nocturnal GH pulse. Important storage: the lyophilized powder must be REFRIGERATED (36–46°F), NOT frozen, and reconstituted solution is stable for only 10–14 days. Side effects from prescribing information include injection-site reactions (~17%) and subclinical hypothyroidism (~6.5%).
Observed Effects & Side Effect Profile
The following observations are derived from preclinical literature and limited early-phase human data. They do not constitute clinical claims.
Reported benefits (research literature)
- Preserves physiologic GH feedback -prevents supraphysiologic elevation
- Former FDA approval (Geref) -established safety and efficacy data
- Pituitary-dependent mechanism maintains natural GH pulsatility
- Bedtime dosing amplifies natural nocturnal GH pulse pattern
Known limitations & side effects
- SPECIAL STORAGE: Lyophilized powder must be REFRIGERATED (36–46°F) -do NOT freeze
- Short reconstituted shelf life (10–14 days only)
- Injection-site reactions in ~17% (from prescribing info)
- Subclinical hypothyroidism in ~6.5% -thyroid monitoring recommended
- Requires functional pituitary -ineffective if pituitary is damaged
Lifestyle Considerations
While the following suggestions are not protocol requirements, research on tissue repair and peptide efficacy consistently highlights these as factors that influence outcomes:
01
Protein intake. Collagen synthesis and tissue remodeling require adequate dietary protein. Research generally supports 1.6–2.2 g/kg/day during active recovery periods.
02
Sleep. The majority of tissue repair and growth hormone secretion occurs during deep sleep stages. 7–9 hours of quality sleep per night supports the biological environment in which recovery peptides operate.
03
Activity balance. Avoid complete immobilization (which impedes collagen remodeling) and overuse (which re-injures tissue). Progressive loading appropriate to the injury stage supports functional recovery.
04
Stress management. Elevated cortisol chronically impairs immune function and tissue repair. Evidence-based stress reduction techniques support the recovery environment.
Injection Technique
Standard subcutaneous injection guidance from clinical best-practice references.
01
Wash hands thoroughly. Clean your work surface. Gather all supplies before beginning.
02
Wipe the vial rubber stopper with a fresh alcohol swab. Allow it to dry completely before inserting a needle.
03
Draw the calculated dose volume into a sterile insulin syringe. Invert the syringe and tap to remove air bubbles; expel them before withdrawing the needle from the vial.
04
Select an injection site: abdomen (at least 2 inches from the navel), outer thigh, or upper outer arm. Clean with a fresh alcohol swab and allow to dry.
05
Pinch a fold of skin between thumb and forefinger. Insert the needle at a 45–90° angle depending on body fat thickness -45° for leaner individuals, 90° for more subcutaneous tissue.
06
Do not aspirate. Current clinical guidelines do not recommend aspiration for subcutaneous injections. Inject slowly and steadily over 2–3 seconds.
07
Wait 3–5 seconds after the plunger bottoms out before withdrawing the needle at the same angle. Apply gentle pressure with a clean swab -do not rub vigorously.
08
Rotate injection sites systematically with every dose. Reusing the same site repeatedly causes lipohypertrophy (hardened fat tissue) which reduces absorption consistency.
09
Dispose of used needles and syringes immediately in a puncture-resistant sharps container. Never recap needles by hand.
Important Notes
⚠
Research use only. Sermorelin is not FDA-approved for human use. Human clinical data may be limited. Do not use without consulting a qualified healthcare professional.
◎
One syringe per injection. Never reuse needles or syringes. Each injection requires a fresh, sterile syringe to prevent contamination and infection risk.
⚠
SPECIAL STORAGE: Lyophilized must be REFRIGERATED (36–46°F) -do NOT freeze
⚠
Short reconstituted shelf life -10–14 days only
⚠
Bedtime administration CRITICAL
⚠
Monitor thyroid -~6.5% subclinical hypothyroidism
◎
Document your protocol. Record daily dose, injection site, and any observations. This supports consistency and allows you to identify patterns or issues over the course of the cycle.
◎
Inspect before each use. The reconstituted solution should be clear and colorless. Discard if cloudy, discolored, or if particulates are visible.
References
All dosing recommendations and mechanism descriptions on this page are derived from the following peer-reviewed publications and regulatory documents.
2
PubMed 18031173
Prakash A et al. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
pubmed.ncbi.nlm.nih.gov/18031173 ↗
